Lineage Cell Therapeutics (LCTX) Short Interest Ratio & Short Volume

Short interest is the volume of Lineage Cell Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 30th, investors have sold 27,740,000 shares of LCTX short. 16.60% of Lineage Cell Therapeutics' shares are currently sold short. Learn More on Lineage Cell Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LCTX shares currently have a short interest ratio of 13.0. Learn More on Lineage Cell Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.60% of Lineage Cell Therapeutics' floating shares are currently sold short.

Lineage Cell Therapeutics saw a decline in short interest in June. As of June 30th, there was short interest totaling 27,740,000 shares, a decline of 3.4% from the previous total of 28,730,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

16.60% of Lineage Cell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Lineage Cell Therapeutics: Anavex Life Sciences Corp. (33.21%), Oric Pharmaceuticals, Inc. (15.84%), LENZ Therapeutics, Inc. (16.33%), Zymeworks Inc. (3.24%), Arcus Biosciences, Inc. (17.20%), Avadel Pharmaceuticals PLC. (13.78%), Cogent Biosciences, Inc. (11.75%), Oculis Holding AG (0.15%), Basilea Pharmaceutica AG (0.01%), Chimerix, Inc. (4.27%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks.

Short selling LCTX is an investing strategy that aims to generate trading profit from Lineage Cell Therapeutics as its price is falling. LCTX shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Lineage Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LCTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LCTX, twice per month. The most recent reporting period available is June, 30 2025.